Cash Flow Statement
Growth Metrics

Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2016 - 2026)

Ani Pharmaceuticals' Amortization of Deferred Charges history spans 12 years, with the latest figure at $351000.0 for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 8.67% to $351000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 million, a 78.57% increase, with the full-year FY2025 number at $1.4 million, up 111.21% from a year prior.
  • Amortization of Deferred Charges hit $351000.0 in Q4 2025 for Ani Pharmaceuticals, down from $838000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for ANIP hit a ceiling of $2.2 million in Q4 2022 and a floor of -$804000.0 in Q4 2021.
  • Historically, Amortization of Deferred Charges has averaged $581684.2 across 5 years, with a median of $590000.0 in 2022.
  • Biggest five-year swings in Amortization of Deferred Charges: crashed 236.73% in 2021 and later surged 372.14% in 2022.
  • Tracing ANIP's Amortization of Deferred Charges over 5 years: stood at -$804000.0 in 2021, then surged by 372.14% to $2.2 million in 2022, then plummeted by 56.49% to $952000.0 in 2023, then crashed by 66.07% to $323000.0 in 2024, then grew by 8.67% to $351000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for ANIP at $351000.0 in Q4 2025, $838000.0 in Q3 2025, and $828000.0 in Q2 2025.